Security Snapshot

BeOne Medicines Ltd. - Common Stock Institutional Ownership

CUSIP: G1146Y101

13F Institutional Holders and Ownership History from Q1 2023 to Q3 2025

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Shares outstanding
1,552,649,190
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • G1146Y101 - BeOne Medicines Ltd. - Common Stock is tracked under CUSIP G1146Y101.
  • Latest finished 13F holder period is not available.
  • 1 significant owner is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 1 to 0 between Q2 2025 and Q3 2025.
  • SEC-reported value moved from $21,276,984 to $0.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

G1146Y101

Latest holder period

n/a

13F holders

13D/G owners

1

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
1
Security
G1146Y101
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Capital International Investors 4.2% -27% 65,211,266 -20% Capital International Investors 31 Mar 2026

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
11
Latest
n/a
Rows shown
1-11 of 11
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 0 $0 -$21,276,984 0
2025 Q2 87,896 $21,276,984 +$21,276,984 $242.07 1
2025 Q1 0 $0 -$627,037 0
2024 Q4 44,600 $627,037 +$627,037 $14.06 1
2024 Q3 0 $0 -$490,212 0
2024 Q2 44,400 $490,212 -$80,598 $11.04 1
2024 Q1 51,700 $628,232 -$7,291 $12.15 1
2023 Q4 52,300 $737,393 -$5,640 $14.10 1
2023 Q3 52,700 $724,000 +$6,869 $13.74 1
2023 Q2 52,200 $715,000 +$52,050 $13.70 1
2023 Q1 48,400 $798,000 +$798,000 $16.49 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .